Literature DB >> 7756647

The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor.

A J Vlot1, S J Koppelman, M H van den Berg, B N Bouma, J J Sixma.   

Abstract

To study the interaction between factor VIII and von Willebrand factor (vWF), binding experiments were performed using immobilized plasma vWF. Plasma was obtained from healthy donors and from patients with severe hemophilia A. For normal and hemophilic vWF, the dissociation constants (kd) for binding of factor VIII to vWF were 0.21 +/- 0.04 and 0.22 +/- 0.05 nmol/L, respectively. At saturation, the stoichiometry was one factor VIII molecule per 50 vWF monomers. In gel-filtration experiments, vWF was saturated by 23 times more factor VIII. However, when this FVIII-vWF complex was immobilized on microtiter plates, the ratio of factor VIII/vWF decreased to the same ratio as in the solid-phase binding assay. To exclude any effect of antibody binding, colloidal gold particles with a diameter of 15 nm were coupled to purified vWF. This vWF-gold complex remained immunoreactive toward polyclonal and monoclonal antibodies, and was able to bind factor VIII, specifically, saturably, and reversibly. After incubation of vWF-gold with factor VIII, unbound and bound factor VIII were separated by centrifugation. Binding isotherms of these fluid-phase binding experiments indicated a kd of 0.32 +/- 0.09 nmol/L and a stoichiometry of approximately 0.5 factor VIII molecule per vWF monomer. We conclude that vWF-binding to a surface, with or without an antibody, may induce a conformational change causing a dissociation of bound factor VIII from vWF.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7756647

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Effect of transmembrane pressure on Factor VIII yield in ATF perfusion culture for the production of recombinant human Factor VIII co-expressed with von Willebrand factor.

Authors:  Seung-Chul Kim; Sora An; Hyun-Ki Kim; Beom-Soo Park; Kyu-Heum Na; Byung-Gee Kim
Journal:  Cytotechnology       Date:  2015-10-13       Impact factor: 2.058

2.  A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.

Authors:  Hendrika Hazendonk; Karin Fijnvandraat; Janske Lock; Mariëtte Driessens; Felix van der Meer; Karina Meijer; Marieke Kruip; Britta Laros-van Gorkom; Marjolein Peters; Saskia de Wildt; Frank Leebeek; Marjon Cnossen; Ron Mathôt
Journal:  Haematologica       Date:  2016-07-06       Impact factor: 9.941

3.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

4.  Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Authors:  Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap
Journal:  Blood Adv       Date:  2021-02-09

5.  FVIII-VWF dos-à-dos.

Authors:  Sriram Krishnaswamy
Journal:  Blood       Date:  2015-08-20       Impact factor: 22.113

6.  Influence of single nucleotide polymorphisms in factor VIII and von Willebrand factor genes on plasma factor VIII activity: the ARIC Study.

Authors:  Marco Campos; Ashley Buchanan; Fuli Yu; Maja Barbalic; Yang Xiao; Lloyd E Chambless; Kenneth K Wu; Aaron R Folsom; Eric Boerwinkle; Jing-fei Dong
Journal:  Blood       Date:  2012-01-04       Impact factor: 22.113

7.  Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.

Authors:  Puneet Gaitonde; Vivek S Purohit; Sathy V Balu-Iyer
Journal:  Eur J Pharm Sci       Date:  2014-10-20       Impact factor: 4.384

8.  The influence of von Willebrand factor on factor VIII activity measurements.

Authors:  S Butenas; B Parhami-Seren; K G Mann
Journal:  J Thromb Haemost       Date:  2008-10-29       Impact factor: 5.824

Review 9.  Blood coagulation factor VIII: An overview.

Authors:  G M Bhopale; R K Nanda
Journal:  J Biosci       Date:  2003-12       Impact factor: 1.826

10.  Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo.

Authors:  Junliang Pan; Thanh Theresa Dinh; Anusha Rajaraman; Mike Lee; Alexander Scholz; Cathrin J Czupalla; Helena Kiefel; Li Zhu; Lijun Xia; John Morser; Haiyan Jiang; Laura Santambrogio; Eugene C Butcher
Journal:  Blood       Date:  2016-05-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.